Evidence map›Paper›PMID 39545771›Full record

ReviewTherapeutic delivery2025

Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.

Heba Mohammed Refat M Selim, Fatma Alzahraa M Gomaa, Mohammad Y Alshahrani, Radwa N Morgan, Khaled M Aboshanab

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Phage therapy againstFrontiers in microbiology · 2026
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heba Mohammed Refat M SelimDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.ORCID 0000-0001-6973-6460
Fatma Alzahraa M GomaaDepartment of Pharmacognosy and Medicinal Herbs, Faculty of Pharmacy, Al-Baha University, Al-Baha, Saudi Arabia.ORCID 0009-0009-7794-5890
Mohammad Y AlshahraniDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.ORCID 0009-0005-3873-4565
Radwa N MorganNational Centre for Radiation Research and Technology (NCRRT), Drug Radiation Research Department, Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt.ORCID 0000-0003-3946-194X
Khaled M AboshanabDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.ORCID 0000-0002-7608-850X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing global health crisis caused by multidrug-resistant (MDR) bacteria necessitates quick interventions to introduce new management strategies for MDR-associated infections and antimicrobial agents' resistance. Phage therapy emerges as an antibiotic substitute for its high specificity, efficacy, and safety profiles in treating MDR-associated infections. Various

Indexed as

Bacterial InfectionsBacteriophagesPhage TherapyAnimalsAnti-Bacterial AgentsBacteriaBiofilmsClinical Trials as TopicDrug Resistance, Multiple, BacterialHumansAnti-Bacterial Agentsantibioticsbacteriophagesmultidrug-resistantphage cocktailPhage therapy

Identifiers

PMID39545771
PMCPMC11875505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.